Arbutus Biopharma (ABUS) News Today $3.64 +0.01 (+0.28%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Arbutus Biopharma Announces Positive Data from Clinical Trials at AASLD - The Liver Meeting® 2024November 17 at 2:05 AM | americanbankingnews.comArbutus Biopharma’s Promising cHBV Treatment ResultsNovember 16 at 5:07 PM | markets.businessinsider.comArbutus Biopharma’s Trial Boosts Hepatitis B TreatmentNovember 16 at 5:07 PM | markets.businessinsider.comArbutus Biopharma to Showcase Innovations at Jefferies London Healthcare ConferenceNovember 16 at 5:07 PM | msn.comArbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Down 16.0% in OctoberArbutus Biopharma Co. (NASDAQ:ABUS - Get Free Report) was the target of a large drop in short interest during the month of October. As of October 31st, there was short interest totalling 6,540,000 shares, a drop of 16.0% from the October 15th total of 7,790,000 shares. Based on an average trading volume of 1,100,000 shares, the days-to-cover ratio is currently 5.9 days.November 16 at 6:28 AM | marketbeat.comArbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of InterferonNovember 15 at 4:21 PM | markets.businessinsider.comArbutus' Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of InterferonNovember 15 at 11:02 AM | globenewswire.comArbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis BNovember 15 at 11:01 AM | globenewswire.comArbutus Biopharma to Present at Jefferies ConferenceNovember 15 at 8:41 AM | markets.businessinsider.comArbutus to Present at Jefferies London Healthcare ConferenceNovember 14 at 7:30 AM | globenewswire.comArbutus Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 14 at 3:03 AM | theglobeandmail.comFY2024 EPS Estimate for Arbutus Biopharma Lowered by AnalystNovember 12, 2024 | americanbankingnews.comHC Wainwright Expects Weaker Earnings for Arbutus BiopharmaArbutus Biopharma Co. (NASDAQ:ABUS - Free Report) - Stock analysts at HC Wainwright decreased their FY2024 earnings per share (EPS) estimates for shares of Arbutus Biopharma in a note issued to investors on Thursday, November 7th. HC Wainwright analyst E. Arce now forecasts that the biopharmaceutNovember 11, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Price Target Raised to $4.50November 10, 2024 | americanbankingnews.comArbutus Biopharma Advances Clinical Trials and Strengthens Financial Position in Q3 2024November 9, 2024 | msn.comArbutus Biopharma’s Promise and Risks: A Hold Rating Amid Early Trial Success and Legal UncertaintyNovember 9, 2024 | markets.businessinsider.comArbutus Biopharma's (ABUS) "Buy" Rating Reaffirmed at HC WainwrightNovember 9, 2024 | americanbankingnews.comArbutus Biopharma (NASDAQ:ABUS) Stock Price Expected to Rise, JMP Securities Analyst SaysNovember 9, 2024 | americanbankingnews.comPromising Potential of Arbutus Biopharma’s Imdusiran in Achieving Functional Cure for Hepatitis B: Ed Arce’s Buy RatingNovember 7, 2024 | markets.businessinsider.comArbutus Biopharma (NASDAQ:ABUS) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $5.00 price objective on shares of Arbutus Biopharma in a research note on Thursday.November 7, 2024 | marketbeat.comQ3 2024 Arbutus Biopharma Corp Earnings CallNovember 7, 2024 | finance.yahoo.comArbutus Fades on Q4 ResultsNovember 7, 2024 | baystreet.caPromising Developments in Arbutus Biopharma’s Pipeline Lead to Buy Rating and Increased Price TargetNovember 7, 2024 | markets.businessinsider.comArbutus Biopharma’s Promising Clinical Developments and Strong Financial Position Justify Buy RatingNovember 7, 2024 | markets.businessinsider.comArbutus Biopharma Corp (ABUS) Q3 2024 Earnings Call Highlights: Promising Clinical Trials and ...November 7, 2024 | finance.yahoo.comArbutus Biopharma Corporation (ABUS) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | seekingalpha.comArbutus Biopharma Corp.November 5, 2024 | wsj.comArbutus Biopharma (ABUS) Set to Announce Quarterly Earnings on WednesdayArbutus Biopharma (NASDAQ:ABUS) will be releasing earnings before the market opens on Wednesday, November 6, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=638746)October 30, 2024 | marketbeat.comArbutus Biopharma Set to Reveal Q3 2024 Results: Save the Date!October 25, 2024 | msn.comArbutus Biopharma to Announce Q3 2024 ResultsOctober 24, 2024 | markets.businessinsider.comArbutus to Report Third Quarter 2024 Financial Results and Provide Corporate UpdateOctober 23, 2024 | globenewswire.comArbutus Biopharma (NASDAQ:ABUS) Sees Strong Trading Volume - Still a Buy?Arbutus Biopharma (NASDAQ:ABUS) Sees Large Volume Increase - Should You Buy?October 16, 2024 | marketbeat.comArbutus Biopharma Target of Unusually High Options Trading (NASDAQ:ABUS)Arbutus Biopharma Co. (NASDAQ:ABUS - Get Free Report) was the recipient of unusually large options trading on Wednesday. Investors acquired 14,379 call options on the company. This is an increase of approximately 1,406% compared to the typical daily volume of 955 call options.October 16, 2024 | marketbeat.comArbutus Biopharma to Showcase Promising Imdusiran Data at Liver ConferenceOctober 16, 2024 | msn.comArbutus Biopharma (NASDAQ:ABUS) Trading Up 5.7% - Still a Buy?Arbutus Biopharma (NASDAQ:ABUS) Shares Up 5.7% - Here's What HappenedOctober 15, 2024 | marketbeat.comArbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024October 15, 2024 | globenewswire.comStrong Buy Rating for Arbutus Biopharma Amidst Promising CHB Treatment DevelopmentsOctober 11, 2024 | markets.businessinsider.comArbutus Biopharma to Present at H.C. Wainwright Viral Hepatitis Virtual ConferenceOctober 2, 2024 | msn.comArbutus to Present at H.C. Wainwright 5th Annual Viral Hepatitis Virtual ConferenceOctober 1, 2024 | markets.businessinsider.comRubric Capital Management LP Invests $5.20 Million in Arbutus Biopharma Co. (NASDAQ:ABUS)Rubric Capital Management LP acquired a new position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,681,090 shares of the biopharmaceutical company's stockSeptember 21, 2024 | marketbeat.comArbutus Biopharma Co. (NASDAQ:ABUS) Short Interest Down 8.7% in AugustArbutus Biopharma Co. (NASDAQ:ABUS - Get Free Report) saw a large drop in short interest in August. As of August 31st, there was short interest totalling 6,060,000 shares, a drop of 8.7% from the August 15th total of 6,640,000 shares. Based on an average daily trading volume, of 1,050,000 shares, the days-to-cover ratio is currently 5.8 days.September 17, 2024 | marketbeat.comArbutus Biopharma Corp Share Price (ABUS.US)September 16, 2024 | lse.co.ukArbutus Biopharma (NASDAQ:ABUS) Shares Down 3.5% Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 3.5%September 12, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Reaches New 12-Month High at $4.56Arbutus Biopharma (NASDAQ:ABUS) Reaches New 12-Month High at $4.56September 9, 2024 | marketbeat.comBuy Rating Affirmed for Arbutus Biopharma Amid Positive Legal and Clinical DevelopmentsSeptember 5, 2024 | markets.businessinsider.comArbutus Biopharma (NASDAQ:ABUS) PT Raised to $7.00Jefferies Financial Group upped their price objective on shares of Arbutus Biopharma from $5.00 to $7.00 and gave the company a "buy" rating in a research note on Thursday.September 5, 2024 | marketbeat.comArbutus Biopharma to Present at Major Investor Conferences in New YorkSeptember 5, 2024 | msn.comArbutus Biopharma (NASDAQ:ABUS) Stock Price Up 5%Arbutus Biopharma (NASDAQ:ABUS) Trading Up 5%September 4, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Reaches New 12-Month High at $4.04Arbutus Biopharma (NASDAQ:ABUS) Hits New 52-Week High at $4.04September 3, 2024 | marketbeat.comArbutus to Participate in Two Upcoming Investor ConferencesSeptember 3, 2024 | globenewswire.com Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Email Address We recommended Nvidia in 2016, now we’re recommending this… (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. ABUS Media Mentions By Week ABUS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABUS News Sentiment▼0.200.56▲Average Medical News Sentiment ABUS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABUS Articles This Week▼193▲ABUS Articles Average Week Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies KALV News KMDA News BYSI News MEIP News RDHL News JANX News DYN News MOR News GMTX News PTGX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABUS) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABUS Stock Alerts